The study, which will be used to support the filing with health authorities worldwide, includes more than 1,100 patients between 51 and 80 years old with a medical history and symptoms of knee osteoarthritis. The study will be conducted mainly in Europe and is estimated to complete in the second half of 2010.
Michael Novinski, president and CEO of Emisphere, said: “The problems associated with osteoarthritis will escalate as the population ages. This Phase III study aims at demonstrating that oral salmon calcitonin, in combination with our Eligen drug delivery technology, may contribute to solving this problem, and also shows that Emisphere is a valuable partner in drug development.”